These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 16289513)

  • 1. Current state of three-dimensional characterisation of antifungal targets and its use for molecular modelling in drug design.
    Ruge E; Korting HC; Borelli C
    Int J Antimicrob Agents; 2005 Dec; 26(6):427-41. PubMed ID: 16289513
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antifungal drug targets: Candida secreted aspartyl protease and fungal wall beta-glucan synthesis.
    Goldman RC; Frost DJ; Capobianco JO; Kadam S; Rasmussen RR; Abad-Zapatero C
    Infect Agents Dis; 1995 Dec; 4(4):228-47. PubMed ID: 8665087
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, synthesis, inhibition studies, and molecular modeling of pepstatin analogues addressing different secreted aspartic proteinases of Candida albicans.
    Cadicamo CD; Mortier J; Wolber G; Hell M; Heinrich IE; Michel D; Semlin L; Berger U; Korting HC; Höltje HD; Koksch B; Borelli C
    Biochem Pharmacol; 2013 Apr; 85(7):881-7. PubMed ID: 23262278
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of new antifungal leads via pharmacophore modeling and QSAR analysis of fungal N-myristoyl transferase inhibitors followed by in silico screening.
    Taha MO; Qandil AM; Al-Haraznah T; Khalaf RA; Zalloum H; Al-Bakri AG
    Chem Biol Drug Des; 2011 Sep; 78(3):391-407. PubMed ID: 21679375
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antifungal agents: mode of action in yeast cells.
    Carrillo-Muñoz AJ; Giusiano G; Ezkurra PA; Quindós G
    Rev Esp Quimioter; 2006 Jun; 19(2):130-9. PubMed ID: 16964330
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [N-myristoyltransferase: a novel antifungal target].
    Zhu J; Sheng CQ; Zhang WN
    Yao Xue Xue Bao; 2005 Sep; 40(9):775-81. PubMed ID: 16342675
    [No Abstract]   [Full Text] [Related]  

  • 8. Modeling and interactions of Aspergillus fumigatus lanosterol 14-alpha demethylase 'A' with azole antifungals.
    Gollapudy R; Ajmani S; Kulkarni SA
    Bioorg Med Chem; 2004 Jun; 12(11):2937-50. PubMed ID: 15142553
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure-based optimization of azole antifungal agents by CoMFA, CoMSIA, and molecular docking.
    Sheng C; Zhang W; Ji H; Zhang M; Song Y; Xu H; Zhu J; Miao Z; Jiang Q; Yao J; Zhou Y; Zhu J; Lü J
    J Med Chem; 2006 Apr; 49(8):2512-25. PubMed ID: 16610794
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Importance of molecular computer modeling in anticancer drug development.
    Geromichalos GD
    J BUON; 2007 Sep; 12 Suppl 1():S101-18. PubMed ID: 17935268
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting virulence: a new paradigm for antifungals.
    Gauwerky K; Borelli C; Korting HC
    Drug Discov Today; 2009 Feb; 14(3-4):214-22. PubMed ID: 19152839
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Natural products as antifungal agents against clinically relevant pathogens.
    Di Santo R
    Nat Prod Rep; 2010 Jul; 27(7):1084-98. PubMed ID: 20485730
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The crystal structure of a major secreted aspartic proteinase from Candida albicans in complexes with two inhibitors.
    Cutfield SM; Dodson EJ; Anderson BF; Moody PC; Marshall CJ; Sullivan PA; Cutfield JF
    Structure; 1995 Nov; 3(11):1261-71. PubMed ID: 8591036
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Currently used antimycotics: spectrum, mode of action and resistance occurrence.
    Francois IE; Aerts AM; Cammue BP; Thevissen K
    Curr Drug Targets; 2005 Dec; 6(8):895-907. PubMed ID: 16375673
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Computer-aided design and synthesis of nonpeptidic plasmepsin II and IV inhibitors.
    Luksch T; Chan NS; Brass S; Sotriffer CA; Klebe G; Diederich WE
    ChemMedChem; 2008 Sep; 3(9):1323-36. PubMed ID: 18752222
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Virtual screening yields inhibitors of novel antifungal drug target, benzoate 4-monooxygenase.
    Berne S; Podobnik B; Zupanec N; Novak M; Kraševec N; Turk S; Korošec B; Lah L; Šuligoj E; Stojan J; Gobec S; Komel R
    J Chem Inf Model; 2012 Nov; 52(11):3053-63. PubMed ID: 23092521
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel inhibitors of trihydroxynaphthalene reductase with antifungal activity identified by ligand-based and structure-based virtual screening.
    Brunskole Svegelj M; Turk S; Brus B; Lanisnik Rizner T; Stojan J; Gobec S
    J Chem Inf Model; 2011 Jul; 51(7):1716-24. PubMed ID: 21667970
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent approaches to antifungal therapy for invasive mycoses.
    Mathew BP; Nath M
    ChemMedChem; 2009 Mar; 4(3):310-23. PubMed ID: 19170067
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bicyclic peptidomimetics targeting secreted aspartic protease 2 (SAP2) from Candida albicans reveal a constrained inhibitory chemotype.
    Calugi C; Trabocchi A; De Bernardis F; Arancia S; Navarra P; Cauda R; Cassone A; Guarna A
    Bioorg Med Chem; 2012 Dec; 20(24):7206-13. PubMed ID: 23123016
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel small molecules for the treatment of infections caused by Candida albicans: a patent review (2002-2010).
    Calugi C; Trabocchi A; Guarna A
    Expert Opin Ther Pat; 2011 Mar; 21(3):381-97. PubMed ID: 21241212
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.